1. Introduction {#sec1}
===============

Crohn\'s disease (CD) is a form of inflammatory bowel disease (IBD) that primarily affects the Caucasian population \[[@B1], [@B2]\]. It is a heritable disease which is influenced by many genetic risk factors \[[@B3]\]. Therefore, identification of gene risk factors of CD is beneficial for the clinical treatment of patients.

Interleukin 23 (IL-23) plays an important role in the inflammatory response against infection as a regulator of immune cells \[[@B4]\]. IL-23R which interacts with IL-23 is a protein consisting of an IL-12*β*1 and an IL-23R chain \[[@B5]\]. Recently, the mechanisms of IL-23R variants have been investigated in different autoimmune diseases \[[@B6]--[@B9]\]. Studies also have shown that rs7517847, the single nucleotide polymorphisms (SNPs) of the*IL23R* gene, are associated with CD occurring rate \[[@B10], [@B11]\]. However, the association between IL-23R polymorphisms and CD susceptibility are inconclusive and controversial due to small sample size in each of the published studies.

To better understand the association of IL-23R polymorphisms and CD susceptibility in Caucasians, we conducted a meta-analysis of all eligible studies and hope to yield more accurate and robust estimates.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We searched for relevant studies in the following databases: EMBASE and PUBMED. Available studies for IL-23R polymorphism and CD were collected by different combinations of various key words: Interleukin-23 receptor, IL-23R; polymorphism, variant, or mutation; Crohn\'s disease, CD. Languages restriction was not imposed in this research and only published studies with full text were included in this meta-analysis.

2.2. Inclusion and Exclusion Criteria of Trials {#sec2.2}
-----------------------------------------------

In the meta-analysis, the following inclusive selection criteria were set: (a) study design evaluating the association between IL-23R polymorphism and CD risk; (b) case control design; (c) Caucasians design. The following exclusive selection criteria were set: (a) no control cases; (b) duplication of the previous publication; (c) no available genotype frequency; for studies with overlapped or repeated data (d) no Caucasians.

2.3. Data Extraction {#sec2.3}
--------------------

Eligible studies were extracted by 2 reviewers (Li Zhang and Yunjie Lu) independently according to the predesigned data collection form. The following information was extracted: first author\'s name, publication year, country, ethnicity, immune suppressive protocol, number of cases and controls, and genotype distribution in both groups. Disagreement was resolved by discussion with a third reviewer (Guozhong Yao).

2.4. Statistical Analysis {#sec2.4}
-------------------------

For each trial, odds ratio (OR) with the 95% confidence interval (95% CI) of the survival rate was derived and calculated. Increased or decreased risk of CD was indicated by 95% CI without 1 for OR. The pooled ORs were estimated for allelic model (T allele versus G allele), homozygote comparison (TT versus GG) and heterozygote comparison (TG versus GG), dominant models (TT/TG versus GG), and recessive model (TT versus TG+GG). *Z* test was performed to assess the significance of the pooled OR. Between-study heterogeneity was assessed by the Cochran\'s *Q* statistic and *I* ^2^ tests \[[@B12]\]. The random effects model was conducted if the *Q* test exhibited a *P* \< 0.05 or the *I* ^2^ test showed \>50%. Otherwise, the fixed effects model would be conducted. For publication bias, the Begg\'s funnel plot and Egger\'s linear regression test were conducted, and *P* \< 0.05 was considered significant.

A fixed-effect model (based on Mantel-Haenszel method) was utilized to pool the data from different studies if the between-study heterogeneity was absent, or a random-effect model (based on DerSimonian and Laird method) was applied.

The statistical analysis was performed by STATA 10.0 (Stata Corp LP, College Station, TX, USA). All *P* values are two-side.

3. Results {#sec3}
==========

3.1. Selection of the Included Studies and Characteristics {#sec3.1}
----------------------------------------------------------

The flow diagram of studies selection and exclusion reasons were represented in [Figure 1](#fig1){ref-type="fig"}. A total of 133 studies were identified by our first research; a number of 41 were preliminarily yielded out after excluding inappropriate studies and screening abstract-screening, full-text assessment. In these 41 studies, 30 were excluded, 11 articles containing rs7517847 in Caucasians were recruited for detailed analysis ([Table 1](#tab1){ref-type="table"}), and these data built [Table 1](#tab1){ref-type="table"} \[[@B13]--[@B23]\]. Each of them was independent. Thus, a total of 3279 CD cases and 4136 healthy controls were included in our meta-analysis. All of them were Caucasian and the diagnosis of CD was based on clinical manifestations and laboratory examinations and further biopsy.

3.2. Evaluation of the Association {#sec3.2}
----------------------------------

The OR from all models indicated a significant association between rs7517847 and CD. After pooling all the eligible studies in [Table 2](#tab2){ref-type="table"}, we found that the risk of CD was significantly associated with rs7517847 in dominant models (TT/TG versus GG: OR = 1.652, 95% CI 1.277, 2.137), allelic model (T allele versus G allele: OR = 1.327, 95% CI 1.198, 1.469), homozygote comparison (TT versus GG: OR = 1.890, 95% CI 1.465, 2.437, [Figure 2](#fig2){ref-type="fig"}), heterozygote comparison (TG versus GG: OR = 1.509, 95% CI 1.161, 1.960), and recessive model (TT versus TG/GG: OR = 1.409, 95% CI 1.279, 1.552). These data demonstrate that rs7517847 increases the risk of CD among Caucasians with hospital-based studies.

3.3. Publication Bias {#sec3.3}
---------------------

Begg\'s funnel plot and Egger\'s test were both performed to assess the publication bias of this meta-analysis. The shape of the funnel plots for homozygote comparison models seemed symmetrical ([Figure 3](#fig3){ref-type="fig"}). Then, the Egger\'s test was used to provide statistical evidence of funnel plot symmetry. The results still did not suggest any evidence of publication bias. Thus, publication bias was not evident in present meta-analyses.

4. Discussion {#sec4}
=============

CD is associated with JAK2 signaling pathway which is activated by IL-23 and IL-23R receptor \[[@B24]\]. Previous studies suggested that the interruption of IL-23R SNPs might lead to the dysregulation of intestinal inflammation \[[@B25]\]. IL-23R gene variants also play an essential role in the development of many autoimmune diseases such as ankylosing spondylitis (AS), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE) \[[@B7], [@B26], [@B27]\]. Therefore, researchers are focusing on observing the relationship between IL-23R gene polymorphisms and the risk of CD. However, the results are conflicting and controversial due to the different races and insufficient sample size. After pooling data for 11 studies in this meta-analysis, our results firstly demonstrate that T allele of rs7517847 was highly susceptible to CD in Caucasians.

One previous study showed that rs7517847 is a protective factor in rheumatoid arthritis (RA) in European population. Interestingly, RA is a systemic autoinflammatory disease which is associated with PTPN22/C1858T, while the organ-specific autoimmune disease CD is not \[[@B28], [@B29]\]. Thus, the mechanism of this genetic variant may not play a common role in different autoimmune diseases. More researches are required to observe the exact mechanisms of IL-23R gene polymorphism.

We should also mention the limitations of this meta-analysis. Primarily, all the studies were limited to the Caucasian. The allelic frequencies may be different in other ethnic groups. Secondly, publication bias might occur even if there is no significance in statistical test due to extracting published studies. Ultimately, owing to methodological limitations, this meta-analysis is retrospective. Two independent authors performed the process of study selection and data extraction and a third author resolved the discrepancy to minimize the bias.

In conclusion, our meta-analysis suggests that IL-23R rs7517847 confers susceptibility to CD in the Caucasians. Furthermore, more studies with larger scale are required to confirm these associations.
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###### 

Characteristics of eligible studies included in the meta-analysis.

  Author                       Year   Country       Ethnicity   Genotyping methods   Case   Control   HWE                     
  ---------------------------- ------ ------------- ----------- -------------------- ------ --------- ----- ----- ----- ----- -------
  Safrany et al. \[[@B13]\]    2013   Hungary       Caucasian   PCR--RFLP            72     110       17    74    138   41    0.081
  Szabo et al. \[[@B14]\]      2013   Hungary       Caucasian   PCR--RFLP            150    182       64    57    99    26    0.104
  Ferguson et al. \[[@B15]\]   2010   New Zealand   Caucasian   MassARRAY            108    172       29    113   183   72    0.892
  Lauriola et al. \[[@B16]\]   2011   Italy         Caucasian   PCR                  9      4         6     13    6     1     0.78
  Lacher et al. \[[@B17]\]     2010   Germany       Caucasian   RT-PCR               81     101       39    78    125   50    0.995
  Latiano et al. \[[@B18]\]    2008   Italy         Caucasian   PCR-RFLP             366    305       52    280   328   108   0.459
  Márquez et al. \[[@B19]\]    2008   Spain         Caucasian   RT-PCR               145    161       36    192   260   94    0.71
  Baptista et al. \[[@B20]\]   2008   Brazil        Caucasian   RT-PCR               59     95        28    79    120   43    0.825
  Newman et al. \[[@B21]\]     2009   England       Caucasian   MassARRAY            195    204       40    300   436   164   0.799
  Okazaki et al. \[[@B22]\]    2008   Canada        Caucasian   RT-PCR               84     91        36    91    157   66    0.91
  Oliver et al. \[[@B23]\]     2007   Spain         Caucasian   Taqman PCR           101    119       18    121   153   68    0.124

###### 

Stratified analysis of rs7517847 polymorphism and CD risk in eligible studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Year   T versus G allele          TT versus GG\              TG versus GG\              TT + TG versus GG\         TT versus TG + GG\
                                                                 OR (95% CI)                OR (95% CI)                (95% CI)                   (95% CI)
  ---------------------------- ------ -------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  **Total**                           **1.327 (1.198, 1.469)**   **1.890 (1.465, 2.437)**   **1.509 (1.161, 1.960)**   **1.652 (1.277, 2.137)**   **1.409 (1.279, 1.552)**

  Safrany et al. \[[@B13]\]    2013   1.357 (1.036, 1.777)       2.347 (1.223, 4.503)       1.922 (1.036, 3.568)       2.070 (1.137, 3.769)       1.371 (0.923, 2.038)

  Szabo et al. \[[@B14]\]      2013   1.102 (0.856, 1.419)       1.069 (0.618, 1.850)       0.747 (0.445, 1.253)       0.865 (0.528, 1.417)       1.337 (0.921, 1.942)

  Ferguson et al. \[[@B15]\]   2010   1.349 (1.084, 1.678)       2.373 (1.432, 3.933)       2.334 (1.446, 3.766)       2.349 (1.481, 3.724)       1.213 (0.879, 1.673)

  Lauriola et al. \[[@B16]\]   2011   0.344 (0.126, 0.941)       0.115 (0.012, 1.129)       0.111 (0.009, 1.309)       0.114 (0.012, 1.062)       0.485 (0.134, 1.754)

  Lacher et al. \[[@B17]\]     2010   1.176 (0.908, 1.523)       1.331 (0.790, 2.243)       1.036 (0.632, 1.698)       1.149 (0.723, 1.828)       1.298 (0.886, 1.902)

  Latiano et al. \[[@B18]\]    2008   1.553 (1.328, 1.816)       2.715 (1.884, 3.913)       1.931 (1.340, 2.784)       2.292 (1.618, 3.248)       1.596 (1.295, 1.968)

  Márquez et al. \[[@B19]\]    2008   1.347 (1.104, 1.643)       1.972 (1.269, 3.063)       1.617 (1.050, 2.489)       1.768 (1.172, 2.665)       1.357 (1.029, 1.791)

  Baptista et al. \[[@B20]\]   2008   1.045 (0.793, 1.377)       1.147 (0.640, 2.055)       1.216 (0.704, 2.100)       1.188 (0.706, 2.000)       0.990 (0.656, 1.492)

  Newman et al. \[[@B21]\]     2009   1.542 (1.302, 1.827)       2.665 (1.805, 3.935)       1.918 (1.307, 2.815)       2.223 (1.541, 3.207)       1.598 (1.265, 2.019)

  Okazaki et al. \[[@B22]\]    2008   1.355 (1.054, 1.741)       1.692 (1.024, 2.798)       1.918 (1.307, 2.815)       1.294 (0.825, 2.029)       1.621 (1.122, 2.342)

  Oliver et al. \[[@B23]\]     2007   1.515 (1.187, 1.935)       3.153 (1.761, 5.648)       2.938 (1.658, 5.207)       3.033 (1.752, 5.252)       1.347 (0.959, 1.891)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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